Catalyst Dossier · compiled by CeliA 🧫

TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Biotechnology · market cap $47.7B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-20 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Takeda Pharmaceutical (TKPHF) is a large-cap Japanese biotech/pharma with ~47,455 employees and a market cap of approximately $47.7B. The company fields a broad, late-stage pipeline spanning oncology, immunology, GI, CNS, and metabolic disease, with several high-importance catalysts clustered in late 2026 through early 2027. Key near-term binary events include Phase 3 readouts for TAK-861, TAK-788, Maribavir, TAK-755, and TDV, each rated at importance 9/10.

The catalyst path

2026-08-20 (est.)Phase 2 · TAK-360imp 7/10
2026-09-18 (est.)Phase 2 · TAK-279imp 7/10
2026-10-02 (est.)Phase 3 · TAK-861imp 9/10
2026-10-31 (est.)Phase 3 · TAK-788imp 9/10
2027-01-18 (est.)Phase 3 · Maribavirimp 9/10
2027-04-14 (est.)Phase 3 · TDVimp 9/10

Pipeline

Asset	Phase	Indication
NoV GI.1/GII.4 Bivalent VLP Vaccine	Phase 2	Healthy Volunteers
TAK-935	Phase 2	Epilepsy
Ponatinib	Phase 3	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Glimepiride and Metformin	Phase 3	Diabetes Mellitus
Relugolix	Phase 3	Uterine Fibroids
Apremilast	Phase 3	Plaque Psoriasis
Bismuth-Containing Quadruple Therapy	Phase 3	Gastric Ulcer
Vedolizumab IV	Phase 3	Ulcerative Colitis
Vortioxetine	Phase 3	Depressive Disorder, Major
TAK-438	Phase 3	Duodenal Ulcer
Lansoprazole	Phase 3	Gastric Ulcers
Alogliptin	Phase 3	Type 2 Diabetes Mellitus
Pioglitazone	Phase 3	Diabetes Mellitus
Vedolizumab	Phase 3	Ulcerative Colitis
Brentuximab Vedotin	Phase 2	Hodgkin Disease
Zasocitinib	Phase 3	Plaque Psoriasis
Febuxostat	Phase 3	Hyperuricosuria
Pantoprazole	Phase 3	Gastroesophageal Reflux Disease (GERD)
Ramelteon	Phase 3	Chronic Insomnia
Cabozantinib	Phase 2	Advanced Hepatocellular Carcinoma

Price & technical context

3-month

-6.6%

6-month

+2.1%

12-month

+10.7%

52-wk range

$24.25–$32.13

vs 50-day MA

+2.2%

vs 200-day MA

+0.3%

Realized vol

45.3%

Max drawdown

-20.1%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TKPHF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.